Seattle Genetics, Inc. and Takeda Pharmaceutical Co. Ltd. Leads Roche in Race to Develop Combo Cancer Therapy

December 2, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Bloomberg -- Seattle Genetics Inc. and Takeda Pharmaceutical Co. may beat Roche Holding AG in developing a new type of combination cancer therapy that’s less toxic than standard treatments.

Twitter
LinkedIn
Facebook
Email
Print

Takeda Roche